Araya Sthefano, Peluso Heather, Doremus Nathan, Lane Jaina, Patel Heli, Talemal Lindsay, Najafali Daniel, Chang Alexander H, Patel Sameer A
From the Division of Plastic and Reconstructive Surgery, Fox Chase Cancer Center, Philadelphia, PA.
Catalyst Medical Consulting, LLC, Simpsonville, SC.
Plast Reconstr Surg Glob Open. 2025 Feb 18;13(2):e6536. doi: 10.1097/GOX.0000000000006536. eCollection 2025 Feb.
We analyzed patient outcomes after deep inferior epigastric perforator (DIEP) flap reconstruction using a national database to assess readmission, mortality, morbidity, and length of stay (LOS).
This retrospective cohort study utilized the 2017-2020 Nationwide Readmissions Database. Patients had an International Classification of Diseases, Tenth Revision procedure code for DIEP flap reconstruction from January to November each year. The primary outcome was the 30-day readmission rate, with secondary outcomes including in-hospital and 30-day mortality, reasons for admission and readmission, and complication rates. Multivariate regression adjusted for confounders.
A total of 32,019 DIEP flap reconstructions were identified, with a median patient age of 51 years. The most common indication was breast reconstruction after mastectomy. In-hospital, 30-day, and calendar-year mortality rates were all under 1% (95% confidence interval [CI]: 1.29-3.99). The 30-day readmission rate was 5.8% (95% CI: 5.4%-6.3%), with infection being the leading cause of readmission (2.0%), a previously unreported finding. Other causes included wound dehiscence (0.19%), pulmonary embolism (0.19%), sepsis (0.18%), and hematoma (0.18%). Reoperation rates were 7% during the index hospitalization and 11% during readmission. The average LOS was 3.7 days (95% CI: 3.65-3.82), consistent with current literature.
This study provides valuable insights into DIEP flap reconstruction outcomes, revealing a 2.0% infection readmission rate. It shows a higher overall readmission rate (7% versus 5.6%) and a lower dehiscence rate (0.2% versus 2.8%) compared with previous data. These findings, derived from the largest nationally representative readmission database in the United States, also demonstrate comparable reoperation rates and LOS.
我们使用一个全国性数据库分析了腹壁下深动脉穿支(DIEP)皮瓣重建术后的患者结局,以评估再入院率、死亡率、发病率和住院时间(LOS)。
这项回顾性队列研究使用了2017 - 2020年全国再入院数据库。患者每年1月至11月有国际疾病分类第十版DIEP皮瓣重建手术编码。主要结局是30天再入院率,次要结局包括住院期间和30天死亡率、入院和再入院原因以及并发症发生率。多变量回归对混杂因素进行了调整。
共识别出32019例DIEP皮瓣重建手术,患者中位年龄为51岁。最常见的适应证是乳房切除术后的乳房重建。住院期间、30天和历年死亡率均低于1%(95%置信区间[CI]:1.29 - 3.99)。30天再入院率为5.8%(95%CI:5.4% - 6.3%),感染是再入院的主要原因(2.0%),这是一个此前未报告的发现。其他原因包括伤口裂开(0.19%)、肺栓塞(0.19%)、脓毒症(0.18%)和血肿(0.18%)。初次住院期间再次手术率为7%,再入院期间为11%。平均住院时间为3.7天(95%CI:3.65 - 3.82),与当前文献一致。
本研究为DIEP皮瓣重建结局提供了有价值的见解,揭示了2.0%的感染再入院率。与先前数据相比,它显示出更高的总体再入院率(7%对5.6%)和更低的裂开率(0.2%对2.8%)。这些来自美国最大的具有全国代表性的再入院数据库的结果,也显示出相当的再次手术率和住院时间。